259 related articles for article (PubMed ID: 24401319)
1. TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers.
Nan J; Du Y; Chen X; Bai Q; Wang Y; Zhang X; Zhu N; Zhang J; Hou J; Wang Q; Yang J
Mol Cancer Ther; 2014 Mar; 13(3):617-29. PubMed ID: 24401319
[TBL] [Abstract][Full Text] [Related]
2. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).
Codony-Servat C; Codony-Servat J; Karachaliou N; Molina MA; Chaib I; Ramirez JL; de Los Llanos Gil M; Solca F; Bivona TG; Rosell R
Oncotarget; 2017 Jul; 8(29):47305-47316. PubMed ID: 28521301
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
4. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y
Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268
[TBL] [Abstract][Full Text] [Related]
5. Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells.
Misumi K; Sun J; Kinomura A; Miyata Y; Okada M; Tashiro S
Cancer Sci; 2016 Apr; 107(4):444-51. PubMed ID: 26825989
[TBL] [Abstract][Full Text] [Related]
6. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib.
Wang J; Wang Y; Zheng C; Hou K; Zhang T; Qu X; Liu Y; Kang J; Hu X; Che X
Cell Biol Int; 2018 Sep; 42(10):1292-1299. PubMed ID: 29885023
[TBL] [Abstract][Full Text] [Related]
8. RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation.
Cho JH; You YM; Yeom YI; Lee DC; Kim BK; Won M; Cho BC; Kang M; Park S; Yang SJ; Kim JS; Kim JA; Park KC
Cell Death Dis; 2018 May; 9(6):587. PubMed ID: 29789542
[TBL] [Abstract][Full Text] [Related]
9. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X
Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257
[TBL] [Abstract][Full Text] [Related]
10. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
Cao W; Liu Y; Zhang R; Zhang B; Wang T; Zhu X; Mei L; Chen H; Zhang H; Ming P; Huang L
Sci Rep; 2015 Jul; 5():8477. PubMed ID: 26166037
[TBL] [Abstract][Full Text] [Related]
11. Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.
Hu Y; Zang J; Cao H; Wu Y; Yan D; Qin X; Zhou L; Fan F; Ni J; Xu X; Sha H; Liu S; Yu S; Wang Z; Ma R; Wu J; Feng J
Oncotarget; 2017 Feb; 8(9):15802-15814. PubMed ID: 28178657
[TBL] [Abstract][Full Text] [Related]
12. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
Bivona TG; Hieronymus H; Parker J; Chang K; Taron M; Rosell R; Moonsamy P; Dahlman K; Miller VA; Costa C; Hannon G; Sawyers CL
Nature; 2011 Mar; 471(7339):523-6. PubMed ID: 21430781
[TBL] [Abstract][Full Text] [Related]
13. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal regulation of miR-206 and IL-6/STAT3 pathway mediates IL6-induced gefitinib resistance in EGFR-mutant lung cancer cells.
Yang Y; Wang W; Chang H; Han Z; Yu X; Zhang T
J Cell Mol Med; 2019 Nov; 23(11):7331-7341. PubMed ID: 31507089
[TBL] [Abstract][Full Text] [Related]
15. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
[TBL] [Abstract][Full Text] [Related]
16. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
Gadgeel SM; Ali S; Philip PA; Wozniak A; Sarkar FH
Cancer; 2009 May; 115(10):2165-76. PubMed ID: 19288574
[TBL] [Abstract][Full Text] [Related]
17. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis by morusin in human non-small cell lung cancer cells by suppression of EGFR/STAT3 activation.
Park HJ; Min TR; Chi GY; Choi YH; Park SH
Biochem Biophys Res Commun; 2018 Oct; 505(1):194-200. PubMed ID: 30243717
[TBL] [Abstract][Full Text] [Related]
19. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH
Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820
[TBL] [Abstract][Full Text] [Related]
20. An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.
Yonesaka K; Takegawa N; Watanabe S; Haratani K; Kawakami H; Sakai K; Chiba Y; Maeda N; Kagari T; Hirotani K; Nishio K; Nakagawa K
Oncogene; 2019 Feb; 38(9):1398-1409. PubMed ID: 30302022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]